Novartis AG ADR buy melinda
Start price
25.05.19
/
50%
€79.30
Target price
04.11.21
€90.20
Performance (%)
-8.45%
End price
05.11.21
€72.60
Summary
This prediction ended on 05.11.21 with a price of €72.60. With a performance of -8.45%, the BUY prediction for Novartis AG ADR by melinda closed slightly in the red. A total of €5.57 was paid as dividends for this prediction. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Novartis AG ADR | 2.222% | 2.222% | 33.981% | 49.351% |
| iShares Core DAX® | 0,36 % | -0,24 % | 3,83 % | 52,26 % |
| iShares Nasdaq 100 | 2,59 % | 1,79 % | 37,83 % | 92,38 % |
| iShares Nikkei 225® | 1,80 % | 7,12 % | 61,36 % | 79,73 % |
| iShares S&P 500 | 1,20 % | 0,93 % | 25,71 % | 66,15 % |
Comments by melinda for this prediction
In the thread Novartis AG ADR diskutieren
NOVARTIS
Novartis AG
Cycadia (sNDA)
décision de la FDA sur Zykadia en première intention - le traitement des patients atteints de cancer du poumon métastatique non à petites cellules (NSCLC) , dont les tumeurs sont kinase lymphatique anaplasique (ALK) - positif
23/08/2017
La FDA approuve l'utilisation prolongée de Zykadia 26, mai 2017
In the thread Trading Novartis AG ADR
Die von melinda gewählte maximale Laufzeit wurde überschritten